SOURCE: Nu-Med Plus, Inc.

Nu-Med Plus, Inc.

September 09, 2015 08:00 ET

Nu-Med Plus Contacted by Global Medical Healthcare Provider

SALT LAKE CITY, UT--(Marketwired - Sep 9, 2015) - Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device company which investigates and develops medical applications of new technologies in the medical field, has been contacted by a major producer of gases for Industry, Health and the Environment to discuss Nu-Med Plus's approach to Inhaled Nitric Oxide(NO) delivery.

Inhaled Nitric Oxide is a medically essential gas that is presently used in Neonate Hypoxia therapy (inadequate oxygen level in newborns) and may have future applications for a variety of other diseases and complications that are currently being investigated.

Mr. Jeff Robins, CEO, Nu-Med Plus., commented, "We welcome the opportunity to speak with companies about our new approaches of administering Inhaled Nitric Oxide(NO) and our complimentary technologies developed for use in the medical health field."

About Nu-Med Plus, Inc.

Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of Nitric Oxide gas for therapeutic use. For more company information please visit

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Contact Information

  • Contact:
    Jeff Robins